Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

August 19, 2013

Nuvilex Outshines Its Peers

Lost in the dog days of August is the remarkable performance of Nuvilex, Inc. (OTCQB – NVLX - $0.145 – Spec Buy) relative to the market and some of its key peers.   Over the past  ten days, while biotech stocks have largely come under pressure, Nuvilex has not only held its own but remains well above its key daily moving averages (DMA).

For example, the NASDAQ Biotechnology Index has declined by nearly 7% during this period but two of Nuvilex’s larger peers, Merrimack Pharmaceuticals and Threshold Pharmaceuticals have really taken it on the chin. Merrimack, a cancer-fighting encapsulation-based biopharmaceutical developer is down roughly 30% on very heavy volume despite favorable development news.  Judging by its short- and intermediate-term trading patterns, Merrimack is clearly out of favor as it is now 32% and 46% below its 50-day and 200-day moving averages respectively. Threshold has fared almost as poorly as it has declined by around 10% during the same period. Again, this drop was not buttressed in the slightest by news of the launch of a new Phase II trial.  While it is incrementally above its 200-day moving average, it is 19% below its 50-day MA. 

Despite all of these bearish signals, Nuvilex has risen incrementally, which is a testament to the building bullish fundamental case for the Company.   In addition to its average daily volume for the past 20 days of 3 million shares which is an increase of almost 50% as compared to the full year average, the stock is 32% higher than its 50-day and more than 300% greater than its 200-day MA.

The combination of a strong technical case for the stock, along with major improvements to the Company’s fundamental outlook, position the stock to test the highs reached during the second quarter of 2013.  This move would coincide with the closing of the Company’s efforts to acquire the rights to the use of the cellulose-based live-cell encapsulation technology in the development of treatments for diabetes, in early 4Q13. 

However, the move could occur even sooner, based on the current herd mentality which is chasing performance at all costs. For those investors and traders seeking alpha in the oncology treatment segment of the biotech world, Nuvilex may be the best option and surely offers the greatest upside in the long term and a series of milestones to drive the stock higher in the near term. 

For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

You Might Also Like

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in these articles was derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.